Development and commercialization of optometry equipment using retinal-scanning technology
First written in FY2021. 6 of 12 entries say "Advanced", first in FY2023-Q3. Latest entry: FY2026.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As announced on 16 October 2025, product recalls and software modifications have been completed, and the product has now made a fresh start as MEOCHECK NEO.」
The eye self-check device restarted as MEOCHECK NEO following the voluntary recall and software modifications. - FY2025WorsenedAnnual report
「However, it was found that the results determined by MEOCHECK and the eye self-check service constituted recommendations to seek medical consultation, and we are proceeding with a voluntary recall and software modifications. All sales activities have been suspended until products compliant with applicable laws and regulations can be brought to market.」
A legal and regulatory compliance issue was identified with MEOCHECK and the eye self-check service, resulting in the suspension of sales activities, a voluntary recall and software modifications. - FY2025-H1Confirmed lower sales and a delay in the delivery schedule for contract developmentAnnual report
「During the interim accounting period, revenue declined from the same period of the previous year due to lower sales of RETISSA NEOVIEWER, a retinal projection viewfinder, and RETISSA MEOCHECK, as well as a delay in the delivery schedule for contract development.」
Revenue in the visual information device business declined from the same period of the previous year due to lower sales of RETISSA NEOVIEWER and RETISSA MEOCHECK and a delay in the delivery schedule for contract development. - FY2024-Q3AdvancedAnnual report
「Revenue increased from the same period of the previous year due to higher sales of RETISSA MEOCHECK, an eye-health screening tool, and higher sales of eye-health screening services, among other factors.」
Sales of RETISSA MEOCHECK and eye-health screening services increased, translating the development of the eye examination equipment and services business into higher revenue. - FY2024-Q2AdvancedAnnual report
「Revenue increased from the same period of the previous year due to higher sales of RETISSA MEOCHECK, an eye-health screening tool, and higher sales of eye-health screening services, among other factors.」
Sales of RETISSA MEOCHECK and eye-health screening services increased, translating the development of the eye examination equipment and services business into higher revenue. - FY2024-Q1RestatedAnnual report
「We expanded sales of existing products and new laser retinal projection products, while also developing the eye-health screening services business.」
The policy of continuing to develop the eye-health screening services business has been reaffirmed. - FY2023AdvancedAnnual report
「In addition to launching the RETISSA MEOCHECK eye-health screening device using laser retinal projection technology, we are launching a service business for transportation operators.」
In addition to sales of MEOCHECK, the company launched eye examination services at taxi companies and indicated its policy of implementing and expanding the services in earnest from fiscal 2023. - FY2023-Q3AdvancedAnnual report
「Revenue increased from the same period of the previous year due to contract development and the launch of eye examination services, among other factors.」
The launch of eye examination services contributed to higher revenue in the laser eyewear business. - FY2022RestatedAnnual report
「With the partner, we are proceeding toward commercialization with proof-of-concept testing and prototyping, as well as the development of a service framework, for a new eye examination device and service scheme using laser retinal projection technology」
The company has reiterated its policy of conducting proof-of-concept testing and prototyping for the eye examination device and eye examination service with its partner, while building the service framework. - FY2021First statedAnnual report
「We are pursuing the joint development, on a contract basis with a domestic medical device manufacturer, of a new eye examination device that enables simple self-screening of visual fields and fundus images simultaneously with a single device.」
Development of the eye examination device is proceeding with the partner, from proof-of-concept and prototyping through commercialization.